sinc
outbreak
rapidli
evolv
pandem
urgent
need
rapid
develop
identif
confirm
efficaci
antivir
prophylaxi
set
exist
drug
chloroquin
cq
hydroxychloroquin
hcq
suggest
evid
efficaci
infect
diseas
becom
prime
candid
reposit
therapeut
prevent
agent
grow
number
clinic
trial
regist
studi
prevent
potenti
atrisk
popul
use
rang
dose
scheme
outcom
measur
rapid
systemat
review
protocol
aim
provid
streamlin
time
synthesi
methodolog
result
random
control
trial
assess
efficaci
cq
hcq
hope
construct
inform
research
well
public
health
polici
sinc
report
outbreak
late
viru
caus
corona
viru
diseas
explod
peopl
suffer
respiratori
diseas
pandem
million
case
current
method
infect
control
larg
confin
public
person
health
measur
vaccin
develop
mayb
much
month
away
deploy
higginsdunn
besid
vaccin
antivir
prophylaxi
major
pharmaceut
intervent
effect
antivir
potenti
prophylact
success
appli
preand
postexposur
viral
infect
de
clercq
case
reposit
old
antimalari
chloroquin
cq
deriv
hydroxychloroquin
hcq
receiv
much
attent
invitro
efficaci
wang
et
al
preliminari
evid
clinic
efficaci
gao
et
al
gautret
et
al
two
agent
thu
propos
potenti
prophylaxi
chang
sun
nicola
esposito
nevertheless
untest
prophylaxi
set
multipl
trial
target
differ
popul
total
propos
enrol
hundr
thousand
subject
worldwid
use
rang
dose
well
outcom
alreadi
regist
date
notwithstand
live
systemat
review
protocol
propos
assess
clinic
trial
maguir
publish
systemat
review
evalu
cq
hcq
role
treatment
kapoor
kapoor
assess
clinic
trial
use
cq
hcq
treatment
specif
exclud
prevent
studi
rana
dulal
yet
protocol
systemat
assess
clinic
trial
address
prevent
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
efficaci
cq
hcq
aim
fulfil
gap
choic
review
methodolog
decid
rapid
systemat
review
tradit
systemat
review
concomit
rigour
methodolog
take
two
year
conduct
may
inordin
long
inform
research
polici
maker
face
rapidli
evolv
pandem
wherea
rapid
review
would
streamlin
form
knowledg
synthesi
gear
inform
time
manner
khangura
et
al
would
suitabl
subject
context
review
manuscript
compli
prefer
report
item
systemat
review
metaanalys
prisma
guidelin
report
systemat
review
metaanalys
shamseer
et
al
protocol
systemat
review
regist
inplasi
http
primari
secondari
tertiari
question
address
review
primari
prophylact
cq
hcq
reduc
risk
infect
b
prophylact
cq
hcq
reduc
sever
subsequ
infect
measur
rang
symptom
laboratori
radiolog
abnorm
need
durat
hospit
icu
stay
subsequ
mortal
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
main
search
resourc
nation
region
intern
clinic
trial
registri
includ
intern
clinic
trial
registri
platform
tabl
search
period
present
date
search
follow
search
term
use
covid
ncov
chloroquin
hydroxychloroquin
elimin
duplic
record
differ
registri
record
reason
exclus
trial
variou
stage
search
well
outlin
select
process
prisma
flow
diagram
includ
trial
sourc
clinic
trial
registri
databas
search
relat
trial
record
identifi
order
supplement
data
extract
addit
corrobor
search
execut
use
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
pubm
cochran
central
regist
control
trial
central
embas
without
languag
public
statu
restrict
infecti
diseas
data
observatori
iddo
websit
document
clinic
trial
registr
relat
maguir
also
consult
order
identifi
articl
might
miss
electron
search
scan
refer
bibliographi
pertin
systemat
review
search
term
evalu
full
text
articl
includ
b
scan
refer
list
select
narr
review
document
relev
subject
c
conduct
crosscit
search
googl
scholar
well
review
relev
news
websit
english
chines
newli
announc
unregist
trial
grey
literatur
search
also
conduct
technic
research
report
plan
activ
complet
clinic
trial
industri
intern
govern
agenc
scientif
research
group
studi
elig
criteria
systemat
review
metaanalysi
assess
accord
establish
particip
intervent
comparison
outcom
studi
design
pico
descript
guyatt
et
al
includ
healthi
atrisk
subject
otherwis
without
contraind
particip
defin
author
trial
studi
includ
subject
alreadi
infect
exclud
intervent
prevent
use
cq
hcq
alon
combin
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
prophylact
agent
restrict
criteria
dosag
durat
time
rout
administr
comparison
placebo
agent
chosen
author
cq
hcq
without
prophylact
agent
versu
placebo
prophylact
agent
treatment
cq
hcq
versu
observ
trial
assess
cq
hcq
plu
agent
elig
cointervent
ident
intervent
comparison
group
use
outcom
exclus
criteria
select
process
includ
outcom
includ
author
trial
group
primari
secondari
outcom
exampl
primari
outcom
includ
seroconvers
incid
preval
subsequ
clinic
diagnosi
laboratori
confirm
infect
diseas
subsequ
sever
diseas
hospit
rate
icu
admiss
rate
death
rate
loss
workhour
number
sick
day
newli
infect
intervent
undertaken
exampl
secondari
outcom
includ
sideeffect
activ
intervent
complianc
rate
primari
secondari
outcom
present
summari
find
tabl
tabl
outcom
present
appendix
random
control
trial
rct
includ
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
use
standardis
form
two
research
independ
extract
data
studi
design
set
particip
characterist
intervent
comparison
detail
includ
dosag
durat
time
rout
administr
outcom
assess
time
measur
well
fund
sourc
conflict
interest
report
author
trial
case
need
clarif
trial
detail
directli
contact
principl
investig
trial
resolv
disagr
discuss
independ
arbit
adjud
unresolv
disagr
two
research
independ
assess
risk
bia
rct
studi
use
jadad
scale
oxford
qualiti
score
system
clark
et
al
compos
five
point
total
two
random
two
blind
one
drop
rate
give
output
refer
qualiti
trial
case
discrep
two
research
third
parti
ask
appli
scale
independ
address
discrep
addit
research
intend
qualit
summar
risk
bia
across
differ
studi
six
domain
random
sequenc
gener
alloc
conceal
blind
method
incomplet
outcom
data
select
outcom
report
bias
referenc
cochran
collabor
network
higgin
et
al
one
trial
clinic
homogen
conduct
metaanalysi
use
revman
nordic
cochran
centr
use
invers
varianc
method
random
effect
model
outcom
data
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
insuffici
calcul
effect
estim
narr
synthesi
employ
binari
outcom
summar
use
risk
ratio
rr
ci
continu
outcom
use
mean
differ
md
standard
deviat
sd
summaris
data
use
ci
mantelhaenszel
method
suess
liu
use
pool
effect
estim
binari
outcom
invers
varianc
continu
outcom
cochran
q
test
use
assess
heterogen
studi
higgin
et
al
test
done
quantifi
heterogen
studi
higgin
thompson
valu
repres
moderatetohigh
heterogen
either
random
fixedeffect
model
use
pool
data
depend
level
heterogen
detect
number
studi
involv
subgroup
analysi
also
perform
identifi
possibl
caus
signific
heterogen
studi
case
identifi
signific
differ
subgroup
test
interact
report
result
separ
least
trial
avail
includ
studi
conduct
funnel
plot
egger
test
check
report
bia
current
protocol
revis
period
adapt
necessari
accord
updat
rct
assess
cq
hcq
prevent
chang
context
pandem
updat
access
onlin
via
inplasi
registri
result
baselin
review
well
updat
publish
preprint
submit
open
sourc
peerreview
journal
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
